English
简体中文
Total: £ 56.28
Published Date: 2026-04-10 | Pages: 120 | Tables: 121 | Pharma & Healthcare
The global Short-acting Interferon Injection market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Short-acting Interferon Injection competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Interferons are proteins that are part of your natural defenses. They tell your immune system that germs or cancer cells are in your body. Interferon injection is a broad-spectrum antiviral agent that does not directly kill or inhibit viruses, but uses cell surface receptors to cause cells to produce antiviral proteins, thereby inhibiting virus replication. Interferons are currently used clinically to treat viral infections such as hepatitis C, cancers including non-Hodgkin’s lymphoma, and autoimmune diseases such as multiple sclerosis.
Short-acting interferon injection is an interferon drug given once daily by intramuscular injection.
The North American market for Short-acting Interferon Injection is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Short-acting Interferon Injection is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Short-acting Interferon Injection include Bayer, Novartis, Biogen, Merck KGaA, Anhui Anke Biotechnology, Beijing Tri-Prime Gene Pharmaceutical, Beijing Kawin Technology, Shan Dong Kexing Biopharm, Shanghai Huaxin High Biotechnology, Harbin Pharmaceutical Group, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Short-acting Interferon Injection market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Short-acting Interferon Injection. The Short-acting Interferon Injection market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Short-acting Interferon Injection market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Short-acting Interferon Injection manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Bayer
Novartis
Biogen
Merck KGaA
Anhui Anke Biotechnology
Beijing Tri-Prime Gene Pharmaceutical
Beijing Kawin Technology
Shan Dong Kexing Biopharm
Shanghai Huaxin High Biotechnology
Harbin Pharmaceutical Group
Sinobioway Biomedicine
3SBio Group
Changchun Heber Biological Technology
Segment by Type
Interferon α1b Injection
Interferon α2a Injection
Interferon α2b Injection
Interferon β1a Injection
Interferon β1b Injection
by Application
Viral Diseases
Malignant Tumors
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Short-acting Interferon Injection manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Short-acting Interferon Injection sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Short-acting Interferon Injection Market Overview
1.1 Product Definition
1.2 Short-acting Interferon Injection by Type
1.2.1 Global Short-acting Interferon Injection Market Value by Type: 2025 vs 2032
1.2.2 Interferon α1b Injection
1.2.3 Interferon α2a Injection
1.2.4 Interferon α2b Injection
1.2.5 Interferon β1a Injection
1.2.6 Interferon β1b Injection
1.3 Short-acting Interferon Injection by Application
1.3.1 Global Short-acting Interferon Injection Market Value by Application: 2025 vs 2032
1.3.2 Viral Diseases
1.3.3 Malignant Tumors
1.4 Global Short-acting Interferon Injection Market Size Estimates and Forecasts
1.4.1 Global Short-acting Interferon Injection Revenue 2021–2032
1.4.2 Global Short-acting Interferon Injection Sales 2021–2032
1.4.3 Global Short-acting Interferon Injection Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Short-acting Interferon Injection Market Competition by Manufacturers
2.1 Global Short-acting Interferon Injection Sales Market Share by Manufacturers (2021–2026)
2.2 Global Short-acting Interferon Injection Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Short-acting Interferon Injection Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Short-acting Interferon Injection, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Short-acting Interferon Injection, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Short-acting Interferon Injection, Product Types and Applications
2.7 Global Key Manufacturers of Short-acting Interferon Injection, Date of Entry into the Industry
2.8 Global Short-acting Interferon Injection Market Competitive Situation and Trends
2.8.1 Global Short-acting Interferon Injection Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Short-acting Interferon Injection Players Market Share by Revenue
2.8.3 Global Short-acting Interferon Injection Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Short-acting Interferon Injection Market Scenario by Region
3.1 Global Short-acting Interferon Injection Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Short-acting Interferon Injection Sales by Region: 2021–2032
3.2.1 Global Short-acting Interferon Injection Sales by Region: 2021–2026
3.2.2 Global Short-acting Interferon Injection Sales by Region: 2027–2032
3.3 Global Short-acting Interferon Injection Revenue by Region: 2021–2032
3.3.1 Global Short-acting Interferon Injection Revenue by Region: 2021–2026
3.3.2 Global Short-acting Interferon Injection Revenue by Region: 2027–2032
3.4 North America Short-acting Interferon Injection Market Facts & Figures by Country
3.4.1 North America Short-acting Interferon Injection Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Short-acting Interferon Injection Sales by Country (2021–2032)
3.4.3 North America Short-acting Interferon Injection Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Short-acting Interferon Injection Market Facts & Figures by Country
3.5.1 Europe Short-acting Interferon Injection Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Short-acting Interferon Injection Sales by Country (2021–2032)
3.5.3 Europe Short-acting Interferon Injection Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Short-acting Interferon Injection Market Facts & Figures by Region
3.6.1 Asia Pacific Short-acting Interferon Injection Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Short-acting Interferon Injection Sales by Region (2021–2032)
3.6.3 Asia Pacific Short-acting Interferon Injection Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Short-acting Interferon Injection Market Facts & Figures by Country
3.7.1 Latin America Short-acting Interferon Injection Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Short-acting Interferon Injection Sales by Country (2021–2032)
3.7.3 Latin America Short-acting Interferon Injection Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Short-acting Interferon Injection Market Facts & Figures by Country
3.8.1 Middle East and Africa Short-acting Interferon Injection Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Short-acting Interferon Injection Sales by Country (2021–2032)
3.8.3 Middle East and Africa Short-acting Interferon Injection Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Short-acting Interferon Injection Sales by Type (2021–2032)
4.1.1 Global Short-acting Interferon Injection Sales by Type (2021–2026)
4.1.2 Global Short-acting Interferon Injection Sales by Type (2027–2032)
4.1.3 Global Short-acting Interferon Injection Sales Market Share by Type (2021–2032)
4.2 Global Short-acting Interferon Injection Revenue by Type (2021–2032)
4.2.1 Global Short-acting Interferon Injection Revenue by Type (2021–2026)
4.2.2 Global Short-acting Interferon Injection Revenue by Type (2027–2032)
4.2.3 Global Short-acting Interferon Injection Revenue Market Share by Type (2021–2032)
4.3 Global Short-acting Interferon Injection Price by Type (2021–2032)
5 Segment by Application
5.1 Global Short-acting Interferon Injection Sales by Application (2021–2032)
5.1.1 Global Short-acting Interferon Injection Sales by Application (2021–2026)
5.1.2 Global Short-acting Interferon Injection Sales by Application (2027–2032)
5.1.3 Global Short-acting Interferon Injection Sales Market Share by Application (2021–2032)
5.2 Global Short-acting Interferon Injection Revenue by Application (2021–2032)
5.2.1 Global Short-acting Interferon Injection Revenue by Application (2021–2026)
5.2.2 Global Short-acting Interferon Injection Revenue by Application (2027–2032)
5.2.3 Global Short-acting Interferon Injection Revenue Market Share by Application (2021–2032)
5.3 Global Short-acting Interferon Injection Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Company Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer Short-acting Interferon Injection Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Bayer Short-acting Interferon Injection Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Company Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Short-acting Interferon Injection Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Novartis Short-acting Interferon Injection Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Biogen
6.3.1 Biogen Company Information
6.3.2 Biogen Description and Business Overview
6.3.3 Biogen Short-acting Interferon Injection Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Biogen Short-acting Interferon Injection Product Portfolio
6.3.5 Biogen Recent Developments/Updates
6.4 Merck KGaA
6.4.1 Merck KGaA Company Information
6.4.2 Merck KGaA Description and Business Overview
6.4.3 Merck KGaA Short-acting Interferon Injection Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Merck KGaA Short-acting Interferon Injection Product Portfolio
6.4.5 Merck KGaA Recent Developments/Updates
6.5 Anhui Anke Biotechnology
6.5.1 Anhui Anke Biotechnology Company Information
6.5.2 Anhui Anke Biotechnology Description and Business Overview
6.5.3 Anhui Anke Biotechnology Short-acting Interferon Injection Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Anhui Anke Biotechnology Short-acting Interferon Injection Product Portfolio
6.5.5 Anhui Anke Biotechnology Recent Developments/Updates
6.6 Beijing Tri-Prime Gene Pharmaceutical
6.6.1 Beijing Tri-Prime Gene Pharmaceutical Company Information
6.6.2 Beijing Tri-Prime Gene Pharmaceutical Description and Business Overview
6.6.3 Beijing Tri-Prime Gene Pharmaceutical Short-acting Interferon Injection Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Beijing Tri-Prime Gene Pharmaceutical Short-acting Interferon Injection Product Portfolio
6.6.5 Beijing Tri-Prime Gene Pharmaceutical Recent Developments/Updates
6.7 Beijing Kawin Technology
6.7.1 Beijing Kawin Technology Company Information
6.7.2 Beijing Kawin Technology Description and Business Overview
6.7.3 Beijing Kawin Technology Short-acting Interferon Injection Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Beijing Kawin Technology Short-acting Interferon Injection Product Portfolio
6.7.5 Beijing Kawin Technology Recent Developments/Updates
6.8 Shan Dong Kexing Biopharm
6.8.1 Shan Dong Kexing Biopharm Company Information
6.8.2 Shan Dong Kexing Biopharm Description and Business Overview
6.8.3 Shan Dong Kexing Biopharm Short-acting Interferon Injection Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Shan Dong Kexing Biopharm Short-acting Interferon Injection Product Portfolio
6.8.5 Shan Dong Kexing Biopharm Recent Developments/Updates
6.9 Shanghai Huaxin High Biotechnology
6.9.1 Shanghai Huaxin High Biotechnology Company Information
6.9.2 Shanghai Huaxin High Biotechnology Description and Business Overview
6.9.3 Shanghai Huaxin High Biotechnology Short-acting Interferon Injection Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Shanghai Huaxin High Biotechnology Short-acting Interferon Injection Product Portfolio
6.9.5 Shanghai Huaxin High Biotechnology Recent Developments/Updates
6.10 Harbin Pharmaceutical Group
6.10.1 Harbin Pharmaceutical Group Company Information
6.10.2 Harbin Pharmaceutical Group Description and Business Overview
6.10.3 Harbin Pharmaceutical Group Short-acting Interferon Injection Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Harbin Pharmaceutical Group Short-acting Interferon Injection Product Portfolio
6.10.5 Harbin Pharmaceutical Group Recent Developments/Updates
6.11 Sinobioway Biomedicine
6.11.1 Sinobioway Biomedicine Company Information
6.11.2 Sinobioway Biomedicine Description and Business Overview
6.11.3 Sinobioway Biomedicine Short-acting Interferon Injection Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Sinobioway Biomedicine Short-acting Interferon Injection Product Portfolio
6.11.5 Sinobioway Biomedicine Recent Developments/Updates
6.12 3SBio Group
6.12.1 3SBio Group Company Information
6.12.2 3SBio Group Description and Business Overview
6.12.3 3SBio Group Short-acting Interferon Injection Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 3SBio Group Short-acting Interferon Injection Product Portfolio
6.12.5 3SBio Group Recent Developments/Updates
6.13 Changchun Heber Biological Technology
6.13.1 Changchun Heber Biological Technology Company Information
6.13.2 Changchun Heber Biological Technology Description and Business Overview
6.13.3 Changchun Heber Biological Technology Short-acting Interferon Injection Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Changchun Heber Biological Technology Short-acting Interferon Injection Product Portfolio
6.13.5 Changchun Heber Biological Technology Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Short-acting Interferon Injection Industry Chain Analysis
7.2 Short-acting Interferon Injection Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Short-acting Interferon Injection Production Mode & Process Analysis
7.4 Short-acting Interferon Injection Sales and Marketing
7.4.1 Short-acting Interferon Injection Sales Channels
7.4.2 Short-acting Interferon Injection Distributors
7.5 Short-acting Interferon Injection Customer Analysis
8 Short-acting Interferon Injection Market Dynamics
8.1 Short-acting Interferon Injection Industry Trends
8.2 Short-acting Interferon Injection Market Drivers
8.3 Short-acting Interferon Injection Market Challenges
8.4 Short-acting Interferon Injection Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Short-acting Interferon Injection Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Short-acting Interferon Injection Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Short-acting Interferon Injection Market Competitive Situation by Manufacturers in 2025
Table 4. Global Short-acting Interferon Injection Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Short-acting Interferon Injection Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Short-acting Interferon Injection Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Short-acting Interferon Injection Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Short-acting Interferon Injection Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Short-acting Interferon Injection, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Short-acting Interferon Injection, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Short-acting Interferon Injection, Product Types and Applications
Table 12. Global Key Manufacturers of Short-acting Interferon Injection, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Short-acting Interferon Injection Companies by Tier (Tier 1, Tier 2, Tier 3), based on Short-acting Interferon Injection Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Short-acting Interferon Injection Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Short-acting Interferon Injection Sales by Region (K Units), 2021–2026
Table 18. Global Short-acting Interferon Injection Sales Market Share by Region (2021–2026)
Table 19. Global Short-acting Interferon Injection Sales by Region (K Units), 2027–2032
Table 20. Global Short-acting Interferon Injection Sales Market Share by Region (2027–2032)
Table 21. Global Short-acting Interferon Injection Revenue by Region (US$ Million), 2021–2026
Table 22. Global Short-acting Interferon Injection Revenue Market Share by Region (2021–2026)
Table 23. Global Short-acting Interferon Injection Revenue by Region (US$ Million), 2027–2032
Table 24. Global Short-acting Interferon Injection Revenue Market Share by Region (2027–2032)
Table 25. North America Short-acting Interferon Injection Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Short-acting Interferon Injection Sales by Country (K Units), 2021–2026
Table 27. North America Short-acting Interferon Injection Sales by Country (K Units), 2027–2032
Table 28. North America Short-acting Interferon Injection Revenue by Country (US$ Million), 2021–2026
Table 29. North America Short-acting Interferon Injection Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Short-acting Interferon Injection Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Short-acting Interferon Injection Sales by Country (K Units), 2021–2026
Table 32. Europe Short-acting Interferon Injection Sales by Country (K Units), 2027–2032
Table 33. Europe Short-acting Interferon Injection Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Short-acting Interferon Injection Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Short-acting Interferon Injection Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Short-acting Interferon Injection Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Short-acting Interferon Injection Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Short-acting Interferon Injection Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Short-acting Interferon Injection Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Short-acting Interferon Injection Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Short-acting Interferon Injection Sales by Country (K Units), 2021–2026
Table 42. Latin America Short-acting Interferon Injection Sales by Country (K Units), 2027–2032
Table 43. Latin America Short-acting Interferon Injection Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Short-acting Interferon Injection Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Short-acting Interferon Injection Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Short-acting Interferon Injection Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Short-acting Interferon Injection Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Short-acting Interferon Injection Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Short-acting Interferon Injection Revenue by Country (US$ Million), 2027–2032
Table 50. Global Short-acting Interferon Injection Sales (K Units) by Type (2021–2026)
Table 51. Global Short-acting Interferon Injection Sales (K Units) by Type (2027–2032)
Table 52. Global Short-acting Interferon Injection Sales Market Share by Type (2021–2026)
Table 53. Global Short-acting Interferon Injection Sales Market Share by Type (2027–2032)
Table 54. Global Short-acting Interferon Injection Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Short-acting Interferon Injection Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Short-acting Interferon Injection Revenue Market Share by Type (2021–2026)
Table 57. Global Short-acting Interferon Injection Revenue Market Share by Type (2027–2032)
Table 58. Global Short-acting Interferon Injection Price (US$/Unit) by Type (2021–2026)
Table 59. Global Short-acting Interferon Injection Price (US$/Unit) by Type (2027–2032)
Table 60. Global Short-acting Interferon Injection Sales (K Units) by Application (2021–2026)
Table 61. Global Short-acting Interferon Injection Sales (K Units) by Application (2027–2032)
Table 62. Global Short-acting Interferon Injection Sales Market Share by Application (2021–2026)
Table 63. Global Short-acting Interferon Injection Sales Market Share by Application (2027–2032)
Table 64. Global Short-acting Interferon Injection Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Short-acting Interferon Injection Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Short-acting Interferon Injection Revenue Market Share by Application (2021–2026)
Table 67. Global Short-acting Interferon Injection Revenue Market Share by Application (2027–2032)
Table 68. Global Short-acting Interferon Injection Price (US$/Unit) by Application (2021–2026)
Table 69. Global Short-acting Interferon Injection Price (US$/Unit) by Application (2027–2032)
Table 70. Bayer Company Information
Table 71. Bayer Description and Business Overview
Table 72. Bayer Short-acting Interferon Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Bayer Short-acting Interferon Injection Product
Table 74. Bayer Recent Developments/Updates
Table 75. Novartis Company Information
Table 76. Novartis Description and Business Overview
Table 77. Novartis Short-acting Interferon Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Novartis Short-acting Interferon Injection Product
Table 79. Novartis Recent Developments/Updates
Table 80. Biogen Company Information
Table 81. Biogen Description and Business Overview
Table 82. Biogen Short-acting Interferon Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Biogen Short-acting Interferon Injection Product
Table 84. Biogen Recent Developments/Updates
Table 85. Merck KGaA Company Information
Table 86. Merck KGaA Description and Business Overview
Table 87. Merck KGaA Short-acting Interferon Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Merck KGaA Short-acting Interferon Injection Product
Table 89. Merck KGaA Recent Developments/Updates
Table 90. Anhui Anke Biotechnology Company Information
Table 91. Anhui Anke Biotechnology Description and Business Overview
Table 92. Anhui Anke Biotechnology Short-acting Interferon Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Anhui Anke Biotechnology Short-acting Interferon Injection Product
Table 94. Anhui Anke Biotechnology Recent Developments/Updates
Table 95. Beijing Tri-Prime Gene Pharmaceutical Company Information
Table 96. Beijing Tri-Prime Gene Pharmaceutical Description and Business Overview
Table 97. Beijing Tri-Prime Gene Pharmaceutical Short-acting Interferon Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Beijing Tri-Prime Gene Pharmaceutical Short-acting Interferon Injection Product
Table 99. Beijing Tri-Prime Gene Pharmaceutical Recent Developments/Updates
Table 100. Beijing Kawin Technology Company Information
Table 101. Beijing Kawin Technology Description and Business Overview
Table 102. Beijing Kawin Technology Short-acting Interferon Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Beijing Kawin Technology Short-acting Interferon Injection Product
Table 104. Beijing Kawin Technology Recent Developments/Updates
Table 105. Shan Dong Kexing Biopharm Company Information
Table 106. Shan Dong Kexing Biopharm Description and Business Overview
Table 107. Shan Dong Kexing Biopharm Short-acting Interferon Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Shan Dong Kexing Biopharm Short-acting Interferon Injection Product
Table 109. Shan Dong Kexing Biopharm Recent Developments/Updates
Table 110. Shanghai Huaxin High Biotechnology Company Information
Table 111. Shanghai Huaxin High Biotechnology Description and Business Overview
Table 112. Shanghai Huaxin High Biotechnology Short-acting Interferon Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Shanghai Huaxin High Biotechnology Short-acting Interferon Injection Product
Table 114. Shanghai Huaxin High Biotechnology Recent Developments/Updates
Table 115. Harbin Pharmaceutical Group Company Information
Table 116. Harbin Pharmaceutical Group Description and Business Overview
Table 117. Harbin Pharmaceutical Group Short-acting Interferon Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Harbin Pharmaceutical Group Short-acting Interferon Injection Product
Table 119. Harbin Pharmaceutical Group Recent Developments/Updates
Table 120. Sinobioway Biomedicine Company Information
Table 121. Sinobioway Biomedicine Description and Business Overview
Table 122. Sinobioway Biomedicine Short-acting Interferon Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Sinobioway Biomedicine Short-acting Interferon Injection Product
Table 124. Sinobioway Biomedicine Recent Developments/Updates
Table 125. 3SBio Group Company Information
Table 126. 3SBio Group Description and Business Overview
Table 127. 3SBio Group Short-acting Interferon Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. 3SBio Group Short-acting Interferon Injection Product
Table 129. 3SBio Group Recent Developments/Updates
Table 130. Changchun Heber Biological Technology Company Information
Table 131. Changchun Heber Biological Technology Description and Business Overview
Table 132. Changchun Heber Biological Technology Short-acting Interferon Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Changchun Heber Biological Technology Short-acting Interferon Injection Product
Table 134. Changchun Heber Biological Technology Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Short-acting Interferon Injection Distributors List
Table 138. Short-acting Interferon Injection Customers List
Table 139. Short-acting Interferon Injection Market Trends
Table 140. Short-acting Interferon Injection Market Drivers
Table 141. Short-acting Interferon Injection Market Challenges
Table 142. Short-acting Interferon Injection Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
Table 146. Authors List of This Report
List of Figures
Figure 1. Product Picture of Short-acting Interferon Injection
Figure 2. Global Short-acting Interferon Injection Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Short-acting Interferon Injection Market Share by Type: 2025 & 2032
Figure 4. Interferon α1b Injection Product Picture
Figure 5. Interferon α2a Injection Product Picture
Figure 6. Interferon α2b Injection Product Picture
Figure 7. Interferon β1a Injection Product Picture
Figure 8. Interferon β1b Injection Product Picture
Figure 9. Global Short-acting Interferon Injection Market Value by Application (US$ Million), 2021–2032
Figure 10. Global Short-acting Interferon Injection Market Share by Application: 2025 & 2032
Figure 11. Viral Diseases
Figure 12. Malignant Tumors
Figure 13. Global Short-acting Interferon Injection Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Short-acting Interferon Injection Market Size (US$ Million), 2021–2032
Figure 15. Global Short-acting Interferon Injection Sales (K Units), 2021–2032
Figure 16. Global Short-acting Interferon Injection Average Price (US$/Unit), 2021–2032
Figure 17. Short-acting Interferon Injection Report Years Considered
Figure 18. Short-acting Interferon Injection Sales Share by Manufacturers in 2025
Figure 19. Global Short-acting Interferon Injection Revenue Share by Manufacturers in 2025
Figure 20. Top 5 and Top 10 Global Short-acting Interferon Injection Players: Market Share by Revenue in Short-acting Interferon Injection in 2025
Figure 21. Short-acting Interferon Injection Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 22. Global Short-acting Interferon Injection Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 23. North America Short-acting Interferon Injection Sales Market Share by Country (2021–2032)
Figure 24. North America Short-acting Interferon Injection Revenue Market Share by Country (2021–2032)
Figure 25. United States Short-acting Interferon Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Canada Short-acting Interferon Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Europe Short-acting Interferon Injection Sales Market Share by Country (2021–2032)
Figure 28. Europe Short-acting Interferon Injection Revenue Market Share by Country (2021–2032)
Figure 29. Germany Short-acting Interferon Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. France Short-acting Interferon Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. U.K. Short-acting Interferon Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Italy Short-acting Interferon Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Russia Short-acting Interferon Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Asia Pacific Short-acting Interferon Injection Sales Market Share by Region (2021–2032)
Figure 35. Asia Pacific Short-acting Interferon Injection Revenue Market Share by Region (2021–2032)
Figure 36. China Short-acting Interferon Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Japan Short-acting Interferon Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. South Korea Short-acting Interferon Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. India Short-acting Interferon Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Australia Short-acting Interferon Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. China Taiwan Short-acting Interferon Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Southeast Asia Short-acting Interferon Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Latin America Short-acting Interferon Injection Sales Market Share by Country (2021–2032)
Figure 44. Latin America Short-acting Interferon Injection Revenue Market Share by Country (2021–2032)
Figure 45. Mexico Short-acting Interferon Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Brazil Short-acting Interferon Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Argentina Short-acting Interferon Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Colombia Short-acting Interferon Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Middle East and Africa Short-acting Interferon Injection Sales Market Share by Country (2021–2032)
Figure 50. Middle East and Africa Short-acting Interferon Injection Revenue Market Share by Country (2021–2032)
Figure 51. Turkey Short-acting Interferon Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Saudi Arabia Short-acting Interferon Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. UAE Short-acting Interferon Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Global Sales Market Share of Short-acting Interferon Injection by Type (2021–2032)
Figure 55. Global Revenue Market Share of Short-acting Interferon Injection by Type (2021–2032)
Figure 56. Global Short-acting Interferon Injection Price (US$/Unit) by Type (2021–2032)
Figure 57. Global Sales Market Share of Short-acting Interferon Injection by Application (2021–2032)
Figure 58. Global Revenue Market Share of Short-acting Interferon Injection by Application (2021–2032)
Figure 59. Global Short-acting Interferon Injection Price (US$/Unit) by Application (2021–2032)
Figure 60. Short-acting Interferon Injection Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
